

First vet vaccine using Algenex technology submitted for European approval

15 Oct 2019 | NEWS



by Joseph Harvey

@JHJournalist

joseph.harvey@informa.com

An unnamed industry partner of Spanish firm Algenex has submitted a veterinary vaccine for European centralized approval.



The potential approval by the European Medicines Agency would validate the use of Algenex's CrisBio technology for manufacturing recombinant subunit vaccines, claims the Madrid-based company.

The specific product under review is a recombinant virus-like particle (VLP) vaccine developed using CrisBio – a patent-protected baculovirus vector-mediated expression platform. According to Algenex, CrisBio “harnesses the power of insects to act as natural single-use bioreactors”. The indication of the vaccine has not yet been revealed.

Algenex has developed its technology platform as an alternative to current bioreactor-based expression technologies. The firm believes CrisBio offers benefits such as linear scalability, reduced production costs and increased productivity (producing gram per liter yields).

Claudia Jiménez, general manager of Algenex, said: “CrisBio has the potential to transform recombinant protein production and this first submission to the EMA by one of our industry partners is a key milestone for Algenex. A potential approval would serve as regulatory validation and pave the way for future regulatory submissions for both vaccines and other biological products.”

She told *Animal Pharm* the unnamed partner will commercialize the vaccine and Algenex will receive “both royalties and income for supply of insect pupae, which are the production tool for the vaccine”.

Algenex claims to have over 200 molecules successfully produced in collaboration with public and private partners. Its collaborators include “multiple international pharmaceutical companies”. The firm is developing vaccines for African swine fever (ASF), avian influenza and porcine circovirus type 2 using the CrisBio platform.

As well as developing CrisBio, Algenex is working on its TopBac system – a plug and play technology that “significantly increases the productivity of existing baculovirus systems”.

Earlier this year, the firm struck up a [partnership with UK business Global DX](#) to develop diagnostics for ASF.

Algenex supports development of recombinant biologics with €4m funding round

By Joseph Harvey

05 Mar 2019

Spanish biotechnology firm Algenex has progressed to its next stage of development after securing approximately €4 million (\$4.5 million) in investment.

[Read the full article here >](#)